solution of the same drug all showed an equally good response rate after four treatment cycles. Reported adverse effects were few and mild. The convenience of having different formulations to offer when prescribing treatment for condylomata must be considered. (Genitourin Med 1995;71:387-390) 
Introduction
In disciplines treating sexually transmitted diseases (STDs) the last decade has been a challenge. A shift from curable infections such as gonorrhoea, chlamydia and syphilis towards treatable but incurable viral diseases such as infections with HPV, HSV and HIV has changed the scene substantially.
Human papilloma virus (HPV) infection is today the most prevalent STD in western countries and accounts for up to 25% of the total attendances in genitourinary medicine (GUM) clinics in the United Kingdom.' Topical application of podophyllin is widely prescribed, although more sophisticated drugs such as interferon have been tried in difficult cases, as well as surgical treatment. Podophyllin, a crude and non-standardised plant extract, has significant local and systemic toxicity. The use of podophyllin may be complicated by severe erosions of the mucus membranes, and patients occasionally have to be hospitalised after such treatment.2 Because of these side effects, applications of podophyllin should be carried out by a physician or a nurse, which places a heavy work load on the medical staff.3 Podophyllotoxin, the main active component of podophyllin, is a purer and more stable product than podophyllin and has a longer shelf-life. Several studies carried out by von Krogh and others have documented the cost-benefit of 05% podophyllotoxin-ethanol treatment applied by the patient twice daily for three days,45 and this has now become the treatment of choice both for female and male patients in the initial treatment of condyloma acuminata. 6 A podophyllotoxin solution can sometimes be difficult to apply and a cream formulation has long been requested by both physicians and patients. Women may especially benefit from a cream formulation, since it is easier to apply the cream with a finger than to apply the solution, for which an applicator must be used.7 The treatment groups were comparable with regard to baseline values with respect to age, duration of lesions, number of lesions, proportions with previously treated STDs and proportions with a regular partner. Totally 16 patients had previously been treated for condylomata. Men under 18 years of age were excluded. Other exclusion criteria were a duration of the present lesions of more than three months, and the presence of intra-anal or anal condylomata, and previous treatment within three months.
The diagnosis was based on clinical examination, and no biopsy specimens for histological examination and HPV detection were obtained. The patients were followed up by the same doctor throughout the study. The patients were informed about the purpose of the study and possible side effects, and that participation was voluntary. All gave their informed consent. The study was (table 1) . The total numbers of lesions at entry into the study in the patients receiving the 0-15% and 0 3% cream formulations were 217 and 220 respectively, and in those treated with the 0.5% solution, 229. Of these 666 lesions, 571 (85 7%) were successfully eradicated at the end of the study. In these three groups the wart clearance rates were 83.4%, 91-4% and 82.5% respectively (table 3). The 03% cream formulation gave the best response rate. Although there was no significant difference in efficacy between the three formulations of podophyllotoxin, we would recommend the 03% cream as an alternative to the 0 5% solution, as the 0.15% cream appears to have a slower onset of action.
As noted by other investigators, the lesion site is of importance for the treatment response.' The best result is observed after treatment on the glans penis and the prepuce, followed by the shaft and other sites. 
